(VRNA) Verona Pharma - Ratings and Ratios

Verona Pharma plc, a biopharmaceutical company specializing in respiratory therapies, focuses on developing and commercializing treatments for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product, Ohtuvayre, is a dual PDE3/PDE4 inhibitor designed to provide both bronchodilator and anti-inflammatory effects, addressing unmet needs in chronic respiratory care. Incorporated in 2005 and headquartered in London, the company has established itself as a clinical-stage biotech with a pipeline targeting severe respiratory conditions.

From a technical perspective, VRNA is currently trading at 64.78, above its SMA 20 (59.16) and SMA 50 (62.73) but significantly above its SMA 200 (42.40). The stock shows a bullish trend in the short term, with an ATR of 3.89 indicating moderate volatility. Resistance is at 67.3, while support levels are at 62.0, 58.6, 53.9, and 40.0. The average 20-day volume is 1,189,300 shares, reflecting moderate trading activity.

Fundamentally, Verona Pharma has a market cap of $7.842 billion, with a forward P/E of 400.00 and a P/B ratio of 25.77, indicating a premium valuation relative to book value. The P/S ratio of 185.50 suggests high expectations for future revenue growth. However, the company currently operates at a loss, with an RoE of -84.81, reflecting its focus on R&D and commercialization efforts.

3-Month Forecast: Based on and , VRNA is expected to test the 67.3 resistance level in the near term. If breached, the stock could trend upward to 70.00, supported by its positive momentum above the SMA 20 and SMA 50. However, if the resistance holds, the stock may consolidate between 62.0 and 67.3. Longer-term, the SMA 200 at 42.40 suggests a potential floor, though the stocks current trajectory indicates continued bullish momentum. Fundamentally, the high forward P/E reflects investor confidence in Ohtuvayres commercial potential, though profitability remains a key milestone for valuation sustainability.